S.J. Harland

Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II

A. Hilary Calvert, S.J. Harland, David R. Newell et al. · Cancer Chemotherapy and Pharmacology · 1982 · 485 citations

Oncology, Medicine, Clinical Studies +4

Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer

Anne O’Donnell, Ian Judson, Mitch Dowsett et al. · British Journal of Cancer · 2004 · 383 citations · Full text

Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report.

M.H. Cullen, Sally Stenning, M C Parkinson et al. · Journal of Clinical Oncology · 1996 · 318 citations

Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function.

S.J. Harland, David R. Newell, Zahid H. Siddik et al. · PubMed · 1984 · 247 citations

Cis-diammine-1,1-cyclobutane Dicarboxylate Platinum, Pharmacotherapy, Free Platinum +17

2-18fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial

M. Bachner, Yohann Loriot, Marine Gross‐Goupil et al. · Annals of Oncology · 2011 · 151 citations

Positron Emission Tomography, Engineering, Medical Imaging +9